Skoulidis and colleagues showed that STK11/LKB1 mutation is associated with less expression of PD-L1 and decreased infiltrative CTL density, resulting in primary resistance to PD-1-based immunotherapies in both human and murine STK11/LKB1-deficient lung adenocarcinoma (72). This evidence concerns the gene STK11 and lung adenocarcinoma.